AOD-9604 Pre-Surgery Hold Window: What Women Need to Know Before Going Under

What Is AOD-9604 and Why Are Women Using It

AOD-9604 is a 16-amino-acid synthetic peptide derived from the C-terminal end of human growth hormone, specifically residues 176 to 191. Unlike full-length growth hormone, it does not bind the GH receptor and does not raise IGF-1 levels. Its proposed mechanism is selective stimulation of lipolysis in adipose tissue through beta-3 adrenergic receptor pathways and inhibition of lipogenesis.

Women are turning to AOD-9604, prescribed through 503A compounding pharmacies, because it promises fat reduction without the androgenic or insulin-resistance side effects associated with full GH therapy. That framing is especially appealing if you have PCOS, perimenopausal metabolic shifts, or a history of weight regain after bariatric surgery.

The Science Behind Its Lipolytic Action

The foundational animal study by Heffernan et al. Published in Endocrinology in 2001 demonstrated that AOD-9604 stimulated lipolysis and reduced body fat in obese mice without activating the GH receptor and without producing the hyperglycemia seen with full-length GH. That distinction matters: the peptide appears to work on fat cells through a pathway that is more peripheral and less systemic than GH itself.

What the 2001 data did not resolve was whether these effects persist in human adipose tissue with the same potency, and whether women's adipose physiology (which is inherently more depot-specific and hormonally responsive than men's) amplifies or blunts those effects.

How It Is Typically Prescribed for Women

In 503A compounding practice, AOD-9604 is most often prescribed as a subcutaneous injection at doses ranging from 250 mcg to 500 mcg per day, usually administered on an empty stomach in the morning. Some protocols add a second injection before sleep. The prescribing clinician sets the dose based on body composition goals, metabolic labs, and hormonal context. Because this is not an FDA-approved finished drug, dosing is not standardized across providers.

The Pre-Surgery Hold Window Explained

The short answer: hold AOD-9604 for at least 72 hours before any elective procedure requiring anesthesia, and discuss a 7-day hold with your surgical and prescribing teams.

The rationale is not that AOD-9604 has a dangerous drug-anesthesia interaction confirmed in human trials. No such trial exists. The rationale is a combination of pharmacokinetic caution, anesthesia team visibility, and the broader principle that unapproved compounded peptides with incompletely characterized tissue half-lives should be paused before procedures where hemodynamic stability and wound healing matter.

Pharmacokinetics and Why the Half-Life Number Is Misleading

AOD-9604's plasma half-life after subcutaneous injection is estimated at approximately 30 minutes based on pharmacokinetic modeling from early development studies. That sounds reassuringly short. The problem is that plasma clearance and tissue-level biological activity are not the same thing.

Beta-3 adrenergic receptor signaling in adipose tissue can persist well beyond the time the peptide is detectable in plasma. Downstream lipolytic cascades, including hormone-sensitive lipase activation and free fatty acid release, may continue for hours after the peptide itself has cleared. This matters perioperatively because elevated circulating free fatty acids can impair platelet aggregation and alter inflammatory signaling at the surgical site.

A 72-hour hold allows approximately 144 plasma half-lives to pass, which is more than enough for plasma clearance. The 7-day hold provides a more conservative buffer for any lingering receptor-level or downstream metabolic effects that current assays cannot easily measure in clinical practice.

What Anesthesiologists Are Actually Concerned About

Anesthesia teams have three practical concerns with patients on compounded peptides like AOD-9604:

1. Hemodynamic variability. Beta-3 adrenergic activity, even peripherally, can influence vascular tone. The degree to which AOD-9604 affects systemic hemodynamics in humans is not established, but the theoretical risk is enough to warrant disclosure and a pause.

2. Drug interaction opacity. Because AOD-9604 is a compounded peptide with no standardized formulation, the anesthesia team cannot look it up in a standard interaction database. Unknown excipients, carrier solutions, and peptide purity vary by compounding pharmacy batch.

3. Wound healing and inflammation modulation. Any agent that alters lipolysis and free fatty acid dynamics in the perioperative window could theoretically affect the inflammatory cascade necessary for normal wound healing. This concern is theoretical for AOD-9604 specifically, but it is the same reasoning applied to other lipolytic or metabolically active compounds before surgery.

Sex-Specific Physiology: Why the Hold Window May Matter More for Some Women

Women's adipose tissue is not just quantitatively different from men's. It is qualitatively different in ways that change how a lipolytic peptide behaves.

Estrogen, Adipose Distribution, and Lipolysis

Estrogen actively regulates fat distribution and lipolysis rates through estrogen receptor-alpha expressed in adipocytes. Premenopausal women preferentially store fat in subcutaneous depots (hips, thighs, gluteal region) rather than visceral depots, partly because estrogen suppresses visceral fat accumulation. This subcutaneous fat is also more lipolytically responsive to catecholamines than visceral fat.

If AOD-9604 works partly through adrenergic pathways, a premenopausal woman with higher baseline estrogen may experience a different magnitude of lipolytic response than a postmenopausal woman with lower estrogen tone. No study has directly measured this interaction.

Perimenopause and Post-Menopause

During perimenopause, estrogen levels fluctuate erratically and visceral fat begins to accumulate even without significant weight gain. Visceral adiposity increases by approximately 44% during the menopause transition, which is partly why women in this life stage are increasingly drawn to AOD-9604 protocols. The metabolic environment in perimenopause also shifts toward insulin resistance, which can alter lipolytic signaling pathways.

For a perimenopausal or postmenopausal woman scheduled for surgery, the pre-surgery hold window conversation should include her menopause practitioner or prescribing provider, not just the surgical team. The intersection of fluctuating hormones, altered fat metabolism, and a compounded peptide is complex enough to warrant an extra layer of clinical communication.

PCOS

If you have PCOS, your adipose tissue may already have altered lipolytic sensitivity related to hyperinsulinemia and androgen excess. Women with PCOS have higher rates of visceral fat for a given BMI and dysregulated lipolysis that contributes to the elevated free fatty acids characteristic of the syndrome. AOD-9604 is sometimes prescribed off-label in PCOS to target this visceral component.

Before surgery, your anesthesiologist and prescribing clinician should know you have PCOS, are on AOD-9604, and when you took your last dose. The combination of PCOS-related metabolic dysregulation and perioperative free fatty acid shifts is not well studied.

Pregnancy, Lactation, and Contraception

AOD-9604 is contraindicated in pregnancy. Stop it immediately if you find out you are pregnant.

This is a non-negotiable clinical position, not a precautionary footnote.

Pregnancy Safety Data

There are no human safety data for AOD-9604 in pregnancy. Zero. The compound has never been studied in pregnant women, and the 503A compounding status means it bypasses the pregnancy pharmacovigilance systems that apply to FDA-approved drugs. Animal teratogenicity studies have not been published for this specific peptide in the peer-reviewed literature accessible to the public.

Growth hormone signaling pathways are active in placental development and fetal growth. While AOD-9604 is designed not to activate the GH receptor, its effects on downstream metabolic and adipose signaling during organogenesis are entirely unknown. Lipolytic agents that significantly raise maternal free fatty acids have been associated with adverse placental lipid transport in animal models. Extrapolating this to AOD-9604 is speculative, but the risk-benefit calculation during pregnancy is clear: no known benefit, unknown risk. Stop it.

If you are trying to conceive, discuss discontinuation timing with your prescribing clinician before you begin attempting pregnancy. A washout period of at least 30 days is a reasonable conservative approach, though no specific evidence-based window exists.

Lactation

AOD-9604 has no lactation transfer data in humans. Peptides of this size (approximately 1,817 daltons) can pass into breast milk to variable degrees depending on their stability, lipophilicity, and transport mechanisms. The AAP and LactMed do not have an entry for AOD-9604, reflecting the absence of any studied data.

The conservative position: do not use AOD-9604 while breastfeeding.

Contraception Requirements

AOD-9604 is not classified as a teratogen in the same legal-regulatory sense as thalidomide or isotretinoin, because it has no human pregnancy data at all rather than demonstrated fetal harm. But the absence of safety data in pregnancy functionally demands reliable contraception during use, for the same reason you would not take an unstudied compound while pregnant.

If you are of reproductive age and sexually active, use effective contraception while on AOD-9604. Discuss this explicitly with your prescribing clinician.

Who This Is Right For (and Who Should Pause or Stop)

AOD-9604 pre-surgery holds apply to everyone on the peptide. But the risk-benefit context around the hold period differs by life stage and indication.

Women Who Are Likely Good Candidates for a Brief (72-Hour) Hold

A 72-hour hold is the minimum reasonable window for a woman who:

• Is postmenopausal, metabolically stable, and on AOD-9604 for body composition support.
• Is undergoing a minor elective procedure (e.g., skin biopsy, minor laparoscopic case) under brief sedation.
• Has disclosed the peptide fully to both her surgical team and her prescribing clinician, who agree on the 72-hour window.
• Has no coagulation concerns, no active wound healing issues, and no PCOS-related metabolic complication.

Women Who Should Use the 7-Day Hold or Longer

A 7-day hold is more appropriate for women who:

• Are undergoing major abdominal surgery, bariatric revision, or any procedure with significant tissue dissection where wound healing matters.
• Have PCOS with documented insulin resistance or dyslipidemia, given the altered free fatty acid dynamics described above.
• Are in active perimenopause with metabolic instability (fluctuating lipids, insulin resistance, weight gain).
• Are on other metabolically active compounds simultaneously (GLP-1 agonists, thyroid medication, metformin) where combined perioperative effects are uncertain.

Women Who Should Not Resume AOD-9604 After Surgery Without Re-evaluation

Surgery changes your body's inflammatory and hormonal environment, sometimes for weeks. Postoperative wound healing requires a functioning inflammatory cascade, and the adipose tissue you are targeting with AOD-9604 is also involved in cytokine production that supports healing. Resuming AOD-9604 immediately after surgery, especially major surgery, has no studied safety data. Wait for your surgical team's clearance, and reconnect with your prescribing clinician before restarting.

Communicating With Your Surgical Team

Disclosure is the single most actionable step you can take.

Many women do not tell their anesthesiologist or surgeon about compounded peptides because they worry about judgment, or because they assume a "natural" or "non-hormonal" compound does not count as a medication worth mentioning. It does.

Your pre-operative medication disclosure should include:

• The full name: AOD-9604 (HGH fragment 176-191).
• The dose and frequency you have been using.
• The date of your last injection.
• The name of your prescribing clinician so the surgical team can call with questions.

Anesthesiologists use medication disclosure to anticipate hemodynamic responses, adjust induction agents, and plan for any unexpected metabolic shifts intraoperatively. The American Society of Anesthesiologists pre-operative evaluation guidelines emphasize comprehensive medication review including supplements and compounded compounds, precisely because these agents are not in standard databases.

A Practical Pre-Surgery Checklist for Women on AOD-9604

Use this framework starting 10 days before your scheduled procedure:

Day 10 before surgery:

• Notify your prescribing clinician of the upcoming procedure.
• Confirm the specific hold window they recommend given your dose and health history.
• Notify your surgeon's office that you are on a compounded peptide.

Day 7 before surgery (if your team recommends the longer hold):

• Take your last AOD-9604 dose.
• Record the date, time, and dose in your medical notes app or a written log to bring to your pre-op appointment.

Day 3 before surgery (minimum hold start for the 72-hour window):

• Take your last AOD-9604 dose if using the 72-hour protocol.

Day of pre-op appointment:

• Bring your peptide vial or prescription label.
• Hand the anesthesiologist the full prescribing information your compounding pharmacy provided.
• Confirm in writing (email or patient portal message) that the surgical team has documented AOD-9604 in your pre-op medication list.

After surgery:

• Wait for explicit surgical clearance before restarting.
• Schedule a follow-up with your prescribing clinician to reassess dosing in the context of post-operative recovery.

What the Evidence Gap Means for You

This bears stating plainly: there are no published human randomized controlled trials studying AOD-9604 pre-surgery hold windows. There are no pharmacokinetic studies in women specifically. The Heffernan et al. 2001 animal data established proof-of-concept lipolysis without GH-receptor activation, but it says nothing about perioperative safety in women.

The 72-hour and 7-day recommendations circulating in compounding medicine practice are expert opinion and pharmacokinetic extrapolation, not guideline-level evidence. Women have been historically underrepresented in peptide pharmacology research, and the scant AOD-9604 human data that exists comes from mixed-sex or male-predominant small studies.

This honesty matters because you deserve to make a decision based on what is actually known versus what is assumed. The hold window recommendation is clinically reasonable. It is not clinically proven. Ask your prescribing clinician directly: "Is your recommendation based on a published protocol, or is this expert consensus?" That question will tell you a great deal about the quality of the practice you are in.

Clinical Update: Where AOD-9604 Stands in 2025

AOD-9604 had an interesting regulatory history. Metabolic Pharmaceuticals developed it as an oral anti-obesity agent (trade name Tyr-hGH Frag 176-191). Phase II trials in the early 2000s showed modest weight loss results in humans. A 2001 phase II study suggested the mechanism was real but the oral bioavailability was limited, and the program stalled. The compound never reached FDA approval as a finished drug product.

In 2023 and 2024, the FDA's increased scrutiny of compounded peptides placed AOD-9604 on a list of compounds under review. As of mid-2025, AOD-9604 remains available through 503A compounding pharmacies when prescribed by a licensed clinician for an identified patient, but its regulatory status is subject to change. FDA 503A compounding regulations require that compounded drugs be prepared for individual patients based on valid prescriptions, using bulk drug substances that meet applicable standards.

Women using AOD-9604 should ask their prescribing clinician at every refill visit whether the regulatory field has changed, because a shift in FDA policy could affect supply and the legal basis for their prescription overnight.